A recently launched Phase IIb randomized clinical trial, led by Sunjay Kaushal, MD, PhD, at Ann & Robert H. Lurie Children’s Hospital of Chicago, uses donor stem cells injected into the patient’s heart during surgery, which is expected to improve right ventricular function of children born with a congenital heart disease called hypoplastic left heart syndrome. Based on a decade of Dr. Kaushal’s pioneering lab research, clinical experience in adults and positive safety results in the Phase I trial, this stem cell-based strategy promises to extend life expectancy for these children.
Daniel Catenacci, MD, a physician-scientist and associate professor of medicine at UChicago Medicine, has received the National Cancer Institute (NCI) 2021 Cancer Clinical Investigator Team Leadership Award (CCITLA).
Scientists from St. Jude Children's Research Hospital have proposed a new method for designing phase II clinical trials and have created a corresponding software to implement the approach.
Researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.
The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm™ (aducanumab).
Registration opens today for the American Society for Radiation Oncology's (ASTRO) 63rd Annual Meeting, which will return to an in-person conference at McCormick Place West in Chicago, October 24-27, 2021. Media resources and registration are available at www.astro.org/astro2021press, and general registration is available at www.astro.org/annualmeeting.
Early 2020 saw the world break into what has been described as a "war-like situation": a pandemic, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the likes of which majority of the living generations across most of the planet have not ever seen.
Researchers at UC San Diego Health have launched a pair of clinical trials to study the immune response of COVID-19 vaccinated transplant recipients of bone marrow and solid organs, such as the heart, lung, liver and kidney.
Researchers have identified a new treatment candidate that appears to not only halt neurodegenerative symptoms in mouse models of dementia and Alzheimer's disease, but also reverse the effects of the disorders.
A new approach using precisely targeted, high-dose radiation to treat invasive kidney cancer proves safe, based on a clinical trial by the UT Southwestern Harold C. Simmons Comprehensive Cancer Center’s kidney cancer program. The study, published in the International Journal of Radiation Oncology*Biology*Physics, could offer new hope for patients with a historically dismal condition.
Vanderbilt University Medical Center (VUMC) is enrolling volunteers ages 12-69 to take part in an NIH funded study to assess reactions to the Pfizer and Moderna COVID-19 vaccines in highly allergic individuals.
Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that suggest a substantial number of patients with prostate cancer may benefit from immunotherapies.
Cedars-Sinai has been awarded $11.99 million by California's stem cell agency to launch a clinical trial testing a potential gene and stem cell therapy for amyotrophic lateral sclerosis (ALS).
The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.
An ongoing international Alzheimer's clinical trial has found that one drug, gantenerumab, improved biomarkers of disease despite unclear cognitive effects, prompting study leaders to offer participants the option of continuing to receive the drug and participate in follow-up examinations as part of a so-called open label extension.
The new medical director for the UC Davis Comprehensive Cancer Center Office of Clinical Research is Dr. Edward Kim who steps into his new position e on July 1, 2021.
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
The Pfizer and Moderna mRNA COVID-19 vaccines is safe for male reproduction, according to a new study by University of Miami Miller School of Medicine researchers published in JAMA , the most widely circulated general medical journal in the world.
On June 14, 2021 at Bhumisirimangalanusorn Building, Chulalongkorn Memorial Hospital, the Thai Red Cross Society, the Faculty of Medicine and the Chula Vaccine Research Center (CVRC), Faculty of Medicine, Chulalongkorn University conducted its first phase of clinical trial on volunteers who have passed the screening process and deemed to be in good health. The process is continuing on to phase 2 to monitor immunity reactions to the ChulaCov19 vaccine under the supervision of medical experts, doctors, nurses and the research team.
The UC Davis Clinical Translational Science Center (CTSC) received notice of its third National Institutes of Health (NIH) award renewal. The 5-year award, almost $33 million, provides critical funding to continue CTSC’s essential services for the UC Davis research community.
Evaluation of three vaccine candidates during the COVID-19 pandemic fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.
The Southwest National Primate Research Center (SNPRC) at Texas Biomed has been awarded more than $37 million from the National Institutes of Health to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe.
The American Society of Anesthesiologists (ASA) asked United States District Judge Madeline Cox Arleo on June 11 to see the “trade libel” suit filed by Pacira BioSciences two months ago for what it is: an egregious and unjustified public relations campaign that seeks to chill scientific research and debate about Pacira’s controversial drug EXPAREL (liposomal bupivacaine). In its case, Pacira disputes the conclusions of peer-reviewed articles and an editorial in the February 2021 issue of Anesthesiology that EXPAREL lacks a comparative benefit over standard bupivacaine, even though it costs 100 times as much.
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
A new study at the University of Chicago Medicine and Washington University found that a single inhalation session with 25% nitrous oxide gas was nearly as effective as 50% nitrous oxide at rapidly relieving symptoms of treatment-resistant depression, with fewer adverse side effects.
Atlantic Health System Cancer Care physicians are lead or co-authors of seven original studies to be presented and published at the 2021 ASCO Annual Meeting, held virtually June 4-8. The ASCO annual meeting is the world’s leading venue for presenting original clinical research on cancer.
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
A 9-year-old patient of Monroe Carell Jr. Children’s Hospital at Vanderbilt is the first in the world to receive an investigational gene editing therapy for Methylmalonic Acidemia (MMA), a rare genetic disorder diagnosed at birth.
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning in a deadly metastatic form, according to results published in The New England Journal of Medicine. The immunotherapy nivolumab was used as an adjuvant therapy, which is given after surgery in the hopes of maximizing its effectiveness.
A treatment regimen for patients with advanced melanoma that combines the immunotherapy agents relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) delayed time to cancer progression significantly more than nivolumab alone, according to results of a study to be presented June 6 at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
New treatment could help people with phenylketonuria (PKU), a genetic disorder that prevents people from metabolizing phenylalanine. Newborns are tested for PKU, which, if not diagnosed early, can have devastating effects. Patients with PKU follow a specific diet for most of their lives.
The U.S. Department of Energy (DOE) announced up to $2 million in new funding to support translational research and development (R&D) of novel, medically relevant isotopes to accelerate evaluation for usage in pre-clinical and clinical trials.
Researchers at Penn State College of Medicine are participating in a national clinical trial evaluating whether people who have previously experienced severe allergic reactions are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.
In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment.
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company's Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia. The study will evaluate the safety and efficacy of infusing multiple dose levels of Thrombosomes versus standard liquid stored platelets.
University Hospitals offers a new technique called PrecisionPoint Transperineal Access System for obtaining a prostate biopsy. The hospital will also conduct a clinical trial to determine if it offers greater benefits than a traditional biopsy.
A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received U.S. Food and Drug Administration (FDA) approval to treat cancer patients with a therapy based on Kachlany’s discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells.
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes.